NSABP B 23--SHORT INTENSIVE AC W/WO TAMOXIFEN W/ CONVENTIONAL CMF

目前的研究正在进行，以确定是否给予 阿霉素和环磷酰胺联合或不联合他莫昔芬治疗4个周期 比施用环磷酰胺、甲氨蝶呤和 5-氟尿嘧啶治疗6个周期，有或没有他莫昔芬。有淋巴结的女性- 阴性乳腺癌和病理性肿瘤大小> 1.0 cm， 接受乳房肿瘤切除术或全乳房切除术和腋窝淋巴结清扫术， 其肿瘤雌激素受体已被测定并发现< 10 fmol/mg胞质溶胶蛋白，通过葡聚糖包被的活性炭或蔗糖- 密度梯度法，或酶免疫测定< 15 fmol/mg 方法将是合格的。如果使用免疫细胞化学测定（ER-ICA） 并且被报告为阴性，它也将是可接受的。某种形式的 必须进行胆甾酮受体分析， 已提交。预后分析可能包括定量或定性 （PR-ICA）方法。患者将按年龄、临床肿瘤 大小和操作类型。

The current study is being conducted to determine whether administering Adriamycin and Cyclophosphamide with or without tamoxifen for four cycles is more effective than administering cyclophosphamide, methotrexate, and 5-fluorouracil for six cycles with or without tamoxifen. Women with node- negative breast cancer and pathological tumor size > 1.0 cm who have undergone lumpectomy or total mastectomy and axillary dissection and whose tumor estrogen receptors have been assayed and found to be < 10 fmol/mg cytosol protein by either the dextran-coated charcoal or sucrose- density gradient methods, or < 15 fmol/mg by the enzyme immunoassay method will be eligible. If the immunocytochemical assay (ER-ICA) is used and is reported as negative, it will also be acceptable. Some form of progesterone-receptor analysis must be perfomred and the results submitted. Progesterone analysis may include quantitative or qualitative (PR-ICA) methods. Patients will be stratified by age, clinical tumor size, and type of operation.